Benefit of Selective Factor Inhibition

Venous thromboembolism (VTE) is a common disease carrying significant morbidity and mortality. In as many as 20% of patients, the initial presentation is sudden death from pulmonary embolism (PE). Despite improved prophylaxis, the incidence of VTE events has not changed significantly since 1980. This situation is not unlike the problem in the prevention of primary and secondary events from coronary heart disease (CHD); lack of progress has …